Lee Pharma to manufacture DRDO's 2-DG Covid Drug

Lee Pharma will manufacture and commercialize the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam, Andhra Pradesh

GN Bureau | June 16, 2021


#2-DG   #CovidDrug   #2DeoxyDGlucose   #DRDO   #CSIR   #LeePharma  
Indian Institute of Chemical Technology, (IICT), a constituent laboratory of CSIR and Lee Pharma, an integrated pharmaceutical company, based in Hyderabad have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG). Recently, 2-DG developed by DRDO and Dr Reddy’s Laboratories has received approval for use in Covid-19 patients. 
 
Lee Pharma will manufacture and commercialize the 2-DG sachets from their formulation facility located at SEZ, Duvvada, Visakhapatnam, Andhra Pradesh, which has the accreditations, by global regulatory agencies.
 
 Dr Srivari Chandrashekar, Director CSIR-IICT highlighted that “There is the role of CSIR in development of 2-DG, as CSIR-CCMB tested the drug on SARS-CoV-2 viral cultures. CSIR has been engaged in the development of drugs for the treatment of Covid-19 and has undertaken many clinical trials for repurposed drugs. Additionally, this agreement with Lee Pharma Ltd. is towards increasing affordable therapeutic options for treatment of Covid-19”.
 
Raghumitra Alla, Director, Lee Pharma said, “This collaboration with CSIR-IICT for 2-DG, API is part of our broader strategy for enhancing Covid-19 treatment options. Further CSIR-IICT, Hyderabad is well-known for its high-quality research & development of various new molecules and we feel proud to be associated with them.”

Comments

 

Other News

Building infrastructure is only half the job

Recent stories of stolen railway wires, disappearing communication towers and missing public infrastructure are often treated as bizarre law-and-order failures of India. Yet they raise a more fundamental question. Why does the State often discover the disappearance of a public asset only after it has alrea

New Delhi’s Indo-Pacific strategy enters a new phase

India appears to be investing fresh dynamism in its Indo-Pacific strategy. At the time when the US, under president Donald Trump, has adopted a conciliatory approach towards China and has changed the name of America’s Indo-Pacific Command to just Pacific Command, India has quietly moved towards con

CAG flags major fiscal lapses in Maharashtra

Maharashtra`s fiscal management has come under sharp scrutiny after the Comptroller and Auditor General (CAG) of India, in its State Finances Audit Report for 2024-25, flagged significant budgetary inefficiencies, accounting irregularities, understatement of key fiscal indicators and widespread governanc

The health sector research we are not doing

Some neglect is loud. This kind is quiet. It sits in research never commissioned, data never collected, questions never asked. In South Asia, that quiet has let the region’s worst health problems stay understudied, underfunded, and out of sight of those who could act.  

Study flags accessibility and last-mile challenges on Mumbai Metro Aqua Line

Mumbai Metro Line 3 (Aqua Line), the city`s first fully underground metro corridor and one of its largest public transport investments, represents a major engineering achievement and has been widely welcomed by commuters. However, the overall commuter experience continues to be constrained by accessibili

Centre intensifies preparedness as El Niño threat looms

Amid uncertainty in the southwest monsoon due to the potential impact of El Niño, the government is addressing the situation with comprehensive preparedness, a clear strategy, and strong ground-level action. While challenges remain, the entire system has been activated in advance and is working proa





Archives

Current Issue

Opinion

Facebook Twitter Google Plus Linkedin Subscribe Newsletter

Twitter